<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94187">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036255</url>
  </required_header>
  <id_info>
    <org_study_id>TL-001</org_study_id>
    <nct_id>NCT02036255</nct_id>
  </id_info>
  <brief_title>Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase</brief_title>
  <official_title>Prevention of Tunneled Cuffed Catheter Malfunction With Prophylactic Use of a Taurolidine Locking Solution Containing Urokinase : a Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to investigate whether the substitution of the standard
      locking solution with a locking solution containing taurolidine and urokinase weekly
      (Taurolock ™ U 25,000 -  www.taurolock.com ) reduces the rate of catheter dysfunction in
      hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Requirement of Urokinase</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Requirement of Urokinase for thrombotic malfunction of dialyse catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Removal of dialysis catheter</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Removal of dialysis catheter for thrombosis and for bacteremia</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of the monthly cost of both procedures</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taurolidine Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taurolock HEP 5000 is used as locking solution after each dialysis session</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurolidine Urokinase</intervention_name>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <other_name>Taurolock Urokinase 25,000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taurolidine Heparin</intervention_name>
    <arm_group_label>Taurolidine Urokinase</arm_group_label>
    <arm_group_label>Taurolidine Heparin</arm_group_label>
    <other_name>Taurolock HEP 5000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, prevalent hemodialysis patients

          -  Informed and consented

          -  Hemodialysis 3x/week via a tunneled cuffed catheter

          -  Urokinase administration at least two times during the previous 6 months

          -  Adequate catheter function during at least one week after the last treatment with
             Urokinase

        Exclusion Criteria:

          -  Presence of heparin-induced thrombocytopenia

          -  Major hemorrhage or intracranial bleeding in the previous 3 months

          -  Pericarditis

          -  Intolerance of Taurolidine

          -  Active catheter-related infection

          -  Last urokinase therapy in the previous 2 weeks before inclusion

          -  Failure to restore the blood flow after Urokinase administration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence FB Bonkain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence FB Bonkain, MD</last_name>
    <phone>003224776055</phone>
    <email>florence.bonkain@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Tielemans, PhD</last_name>
    <phone>003224776055</phone>
    <email>christian.tielemans@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bracops Hospital</name>
      <address>
        <city>Anderlecht</city>
        <state>Brussels</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Vandervelde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique Vandervelde, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ixelles Hospital</name>
      <address>
        <city>Ixelles</city>
        <state>Brussels</state>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Libertalis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Libertalis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brugman Hospital</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Mesquita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Martin Wissing, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RHMS</name>
      <address>
        <city>Baudour</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Debelle, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Frederic Debelle, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Treille</last_name>
    </contact>
    <investigator>
      <last_name>Serge Treille, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Vésale</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Madhoun</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Madhoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHWAPI</name>
      <address>
        <city>Tournai</city>
        <state>Hainaut</state>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Claude Stoléar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Claude Stoléar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jean Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, LeBlanc M, Faris P, Barre P, Zhang J, Scott-Douglas N; Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin Study Group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med. 2011 Jan 27;364(4):303-12. doi: 10.1056/NEJMoa1011376.</citation>
    <PMID>21268722</PMID>
  </reference>
  <reference>
    <citation>Trerotola SO, Johnson MS, Harris VJ, Shah H, Ambrosius WT, McKusky MA, Kraus MA. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. Radiology. 1997 May;203(2):489-95.</citation>
    <PMID>9114110</PMID>
  </reference>
  <reference>
    <citation>Di Iorio BR, Bellizzi V, Cillo N, Cirillo M, Avella F, Andreucci VE, De Santo NG. Vascular access for hemodialysis: the impact on morbidity and mortality. J Nephrol. 2004 Jan-Feb;17(1):19-25.</citation>
    <PMID>15151255</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Bonkain Florence</investigator_full_name>
    <investigator_title>Bonkain Florence, MD, UZ Brussel</investigator_title>
  </responsible_party>
  <keyword>Prevention, Thrombosis, Hemodialysis, Vascular access device</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Taurolidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
